Listing of NABTT Presentations, Abstracts, and Publications

 

Manuscripts Submitted:

 

1)    Chiocca EA., Abbed KM., Tatter S, Louis DN, Hochberg FH, Barker F, Kracher J, Grossman SA, Fisher J, Carson K, Rosenblum M, Mikkelsen T, Olson J, Markert J, Rosenfeld S, Nabors, LB, Brem S, Phuphanich S, Freeman S, Kaplan R, Zwiebel J. A Phase I, Open-Label, Dose-Escalation, Multi-Institutional Trial of Intratumoral Injection with an E1B-Attenuated Adenovirus, ONYX-015, into Recurrent Malignant Gliomas.  Submitted to Molecular Therapy 2004

 

2)    Rudek MA., Hartke C., Zabelina, Y., Zhao M., New P., Baker SD.,  A sensitive method for determination of COL-3, a chemically modified tetracycline, in human plasma using high-performance liquid chromatography and ultraviolet detection.  Submitted to J Pharmaceutical and Biomedical Chromatography 2003.

 

3)    Brem, S., Grossman, S.A., Carson, K.A., New, P., Phuphanich S, Alavi JB, Mikkelsen T, Fisher J, Phase II Trial of Copper Depletion as Angiosuppressive Treatment in Newly Diagnosed Glioblastoma Multiforme, Submitted JCO 2004

 

4)   Phuphanich S, Baker SD, Grossman SA, Gilbert MR, Fisher JD, Carson KA, Carducci MA, Oral Sodium Phenylbutyrate in Patients with Recurrent Malignant Gliomas: A Dose Escalation and Pharmacologic Study, Submitted Neuro-Oncology 2004

  

 

Manuscripts Published or In Press:

 

1)   Fetell MR, Grossman SA, Fisher J, Erlanger B, Rowinsky E, Stockel J, Piantadosi S.  Pre-irradiation paclitaxel in glioblastoma multiforme:   Efficacy, pharmacology, and drug interactions.  Journal of Clinical Oncology 15:3121-3128, 1997.

 

2)     Piantadosi S, Fisher JD, Grossman SA.  Practical implementation of the continual reassessment method for dose finding trials.  Cancer Chemotherapy and Pharmacology.  41:429-436, 1998.

 

3)     Grossman SA, Hochberg F, Fisher JD, Chen TL, Kim L, Gregory R, Grochow LB, Piantadosi S. for the NABTT CNS Consortium.  Increased dose requirements for 9-aminocamptothecin and altered pharmacokinetics in patients on anticonvulsants.  Cancer Chemotherapy and Pharmacology.  42:118-126, 1998.

 

4)     Grossman SA, Fisher JD, Piantadosi S, Brem H.  The New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium:  Organization, Objectives, and Activities.  Cancer Control 5:107-114, 1998.

  

5)     Kleinberg L, Grossman SA, Piantadosi S, Pearlman J, Engelhard H, Lesser G, and Gerber M.  A Phase I Trial to Determine the Safety, Pharmacodynamics and Pharmacokinetics of RSR13, A Novel Radioenhancer, in Newly Diagnosed Glioblastoma. Journal of Clinical Oncology 17:2593-2603, 1999.

 

6)     Hochberg, F, Grossman SA, Mikkelsen T, Glantz M, Fisher JD, Piantadosi S.  Lack of Efficacy of 9-Aminocamptothecin in Adults with Newly Diagnosed Glioblastoma Multiforme and Recurrent High Grade Astrocytomas.  Neuro-Oncology, 2:29-33, 2000.

 

7)     Grossman, SA., Phuphanich, S., Lesser, G., Rozental J., Grochow, LB., Fisher, JD., Piantadosi, S., for the NABTT CNS Consortium.  Toxicity, Efficacy, and Pharmacology of Suramin in Adults with Recurrent High Grade Astrocytomas. Journal Clinical Oncology, 19 (13): 3260-3266, 2001.

 

8)     Kleinberg L, Grossman SA, Carson K, Lesser G, O’Neill A, Pearlman J, Phillips P, Herman T, and Gerber M for the New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium, Baltimore MD.  Survival of patients with newly diagnosed GBM treated with RSR13 and radiotherapy:  Results of a phase II NABTT CNS consortium safety and efficacy study.  Journal Clinical Oncology, 15, 20 (4): 3149-55, 2002.

 

9)    Baker, MJ., Brem, S., Daniels, S., Sherman, B., and Phuphanich, S.  Complete Response of a Recurrent, Multicentric Malignant Glioma in a Patient Treated with Phenylbutyrate.  J of Neuro-Oncology, 2002.

 

10) Batchelor T, Carson K, O’Neill A, Grossman SA, Alavi J, New P, Hochberg F, and Priet R  Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.  Journal of Clinical Oncology, 21(6): 1044-1049, 2003.

 

11) Olivi A, Grossman SA, Tatter S, Barker F, Judy K, Olson J, Bruce J, Hilt D, Fisher J, Piantadosi S. New Approaches to Brain Tumor Therapy CNS Consortium.  Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma. A New Approaches to Brain Tumor Therapy CNS Consortium Trial. Journal of Clinical Oncology, 21 (9): 1845-1849, 2003.

 

12) Gilbert MR., Supko JG, Batchelor T, Lesser G, Fisher JD, Piantadosi S, Grossman S.  Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.  Clinical Cancer Research 9 (8): 2940-2949, 2003.

 

13) Tatter SB, Shaw EG, Rosenblum ML, Karvelis K, Kleinberg L, Weingart J, Olson JJ, Crocker IR, Brem S, Pearlman JL, Fisher JD, Carson K, Grossman SA.  New Approaches to Brain Tumor Therapy CNS Consortium. An inflatable balloon catheter and liquid I-125 radiation source (GliaSite Radiation Therapy System) for the treatment of recurrent malignant glioma:  multicenter safety and feasibility trial.  Journal of NeuroSurgery, 99(2): 297-303, 2003.

 

14) Mihaila D, Gutiérrez JA, Rosenblum ML, Newsham IF, Bögler O, Rempel SA. Meningiomas: Analysis of Loss of Heterozygosity on Chromosome 10 in Tumor Progression and the Delineation of Four Regions of Chromosomal Deletion in Common With Other Cancers. Clin Cancer Res, 9 (12): 4435-42, 2003.

 

15) Mihaila D, Jankowski M, Gutiérrez JA, Rosenblum ML, Newsham IF, Bögler O,

Rempel SA. Meningiomas: Loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival.   Clin Cancer Res, 9 (12): 444-4451, 2003.

 

16) He X, Batchelor T, Grossman S, Supko J, for the New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium. Determination of procarbazine in human plasma by liquid chromatography with electrospray ionization mass spectrometry.  J. Chromatogr B Analyt Technology Biomed Life Sci, 799(2) 281-291, 2004.

 

17) Laterra JJ, Grossman SA, Carson KA, Lesser Gj, Hochberg FH, Gilbert MR.   Suramin and radiotherapy in newly diagnosed glioblastoma: Phase II NABTT CNS Consortium Study.  Neuro-Oncology, 6 (1): 15-20 2004

 

18) Batchelor TT, Gilbert MR, Supko JG, Carson KA, Nabors LB, Grossman SA, Lesser GJ, Mikkelsen T, Phuphanich S, NABTT CNS Consortium.  Phase 2 Study of Weekly Irinotecan in Adults with Recurrent Malignant Glioma:  Final report of NABTT 97-11.  Neuro-Oncology 6 (1): 21-27, 2004.

 

19) Grossman S, Alavi JB, Supko JG, Carson KA, Priet R, Dorr JS, Grundy JS, Holmlund J for the New Approaches to Brain Tumor Therapy CNS Consortium.  Efficacy and Toxicity of an Antisense Oligonucleotide Directed Against Protein Kinase C-a(Aprinocarsen) Delivered as 21-Day Continuous Intravenous Infusion in Patients with Recurrent High Grade Astrocytomas. Neuro-Oncology (In press, 2004). 

 

Presentations and Abstracts:

 

1)   Fetell MR, Grossman SA, Balmaceda C, Leu J-G, Erlanger BF, Rowinsky E, Khandji AG, Yue N, Zeltzman M.  Clinical and Pharmacologic Study of Pre-irradiation Taxol Administered as a 96-hour Infusion in Adults with Newly Diagnosed Glioblastoma Multiforme (GBM),  Proc. Am. Soc.  Clin.  Oncol., 13:179, 1994.

 

2)   Fetell MR, Grossman SA, Fisher JD, Erlanger B, Stockel J, Piantadosi S.  Pre-irradiation Paclitaxel in Glioblastoma Multiforme (GBM):  Efficacy, Pharmacology, and Drug Interactions.  Proc.  Am. Soc. Clin. Oncol., 15:153, 1996.

 

3)   Grossman SA.  “Reduced toxicity and steady state concentrations of 9-aminocamptothecin (9-AC) in patients on anticonvulsant:  Implication for clinical brain tumor trials.”  Annual Fall Phase I Meeting, National Cancer Institute, Bethesda, MD, September, 1996.

 

4)   Grossman, SA.  “Research Directions of the NABTT CNS Consortium” 11th International Conference on Brain Tumor Research and Therapy, Silverado Country Club and Resort, Napa, California.  October, 1996.

 

5)   Amey M, Kaplan R, Grossman SA.  Program Income:  A novel approach to expand the activities of The NABTT CNS Consortium.  Annual Meeting of the National Council of University Research Administrators, Washington, D.C.  November, 1996.

 

6)   Grossman SA.  Reduced toxicity and steady state concentrations of 9-aminocamptothecin (9-AC) in patients on anticonvulsants:  Implications for clinical brain tumor trials.  Scientific Meeting of the Society of Neuro-Oncology, Santa Fe, New Mexico.  November, 1996.

 

7)   Grossman SA, Hochberg F, Fisher J, Chen TL, Kim L, Grochow LB, Piantadosi S, for the NABTT CNS Consortium.  Reduced toxicity and steady state concentrations of 9-aminocamptothecin (9-AC) in patients on anticonvulsants:  Implications for clinical brain tumor trials.  Proc Society for Neuro-Oncology, 1996.

 

8)   Grossman SA, Hochberg F, Fisher J, Chen TL, KIM L, Gregory R, Grochow LB, Piantadosi S. for the NABTT CNS Consortium.  Increased 9-aminocamptothecin (9-AC) dose requirements in patients on anticonvulsants.  Proc. Am. Soc. Clin. Oncol, 16:389, 1997.

 

9)   Piantadosi S, Fisher J, Grossman SA.  Practical implementation of the continual reassessment method for dose finding trials.  Proc Am Soc Clin Oncol, 16:247, 1997.

 

10) Kleinberg L, Grossman SA, Priet R, Sheidler V, Fisher J.  RSR13:  Initial Safety and Pharmacodynamic Results in Newly Diagnosed Glioblastoma Multiforme (GBM).  Soc Neuro-Onc Vol 2, 74, 1997.

 

11) Hochberg F, Grossman SA, Mikkelsen T, Calabresi P, Fisher J, Piantadosi S.  For the NABTT CNS Consortium.  Efficacy of 9-aminocamptothecin (9-AC) in Adults with Newly Diagnosed Glioblastoma Multiforme (GBM) and Recurrent High Grade Astrocytomas (HGA).  Proc Am Soc Clin Oncol, 17:388, 1998.

 

12) Piantadosi S, Fisher J, Grossman SA.  Validation of Doses Selected using the Continual Reassessment Method (CRM) in Patients with primary CNS Malignancies.  Proc Am Soc Clin Oncol, 17:212, 1998.

 

13) Olivi A, Bruce J, Saris S, Engelhard H, Judy K, Kelly D, Burak E, Dal Pan G, Grossman S, Fisher J, Piantadosi S, For the NABTT CNS Consortium and Guilford Pharmaceuticals, Inc.  Phase I Study of Escalating Doses of Interstitial BCNU Administered via Wafer in Patients with Recurrent malignant Glioma (MG).  Proc Am Soc Clin Oncol, 17:1490, 1998.

 

14) Grossman SA, Fisher J, Piantadosi S.  For the NABTT CNS Consortium.  The NABTT Glioblastoma Database:  An Objective Means to Select Novel Agents for phase III Testing.  Proc Am Soc Clin Oncol, 17:406, 1998.

 

15) Kleinberg L, Grossman SA, Piantadosi S, Shaw E, Grous H, Engelhard H, Priet R, Sheidler V.  For the NABTT CNS Consortium.  Initial Phase IB Results with RSR13, A Novel Radio-Enhancer, in Patients with Newly Diagnosed Glioblastoma (GBM).  Proc Am Soc Clin Oncol, 17:388, 1998.

 

16) Kleinberg L, Grossman SA, Piantadosi S, Pearlman